| High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. | |
| | |
MedLine Citation:
|
PMID: 16541327 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Variants of survivin with differing subcellular localizations might mediate the different functions of survivin, i.e. cell-cycle regulation and apoptosis inhibition. Highly proliferative tumors are more sensitive to chemotherapy, whereas apoptosis resistant cells would be refractory to endocrine therapy. Possibly, this explains incongruent data on the association of survivin with prognosis in breast cancer. Survivin levels were measured using ELISA in 800 x g pellets and 100,000 x g supernatants of breast cancer tissues from patients that were treated with either chemotherapy or endocrine therapy for advanced disease. These fractions might be enriched with nuclear or cytoplasmatic located survivin variants. Survivin levels were associated with tumors with poor prognostic clinical characteristics. For the patients treated with endocrine therapy, the patients with high survivin levels exhibited a significantly shorter progression free survival (PFS) than those who had low levels (pellet survivin Hazard Ratio (HR)=2.74, 95% Confidence Interval (CI)=1.31-5.72, p=0.008 and median PFS 5.8 versus 8.6 months, p=0.006, log-rank; cytosolic survivin HR=3.03, 95% CI=1.45-6.35, p=0.003). In contrast, for patients treated with chemotherapy, those with high cytosolic survivin had a significantly longer PFS than those with low levels (median PFS of 6.2 months, versus 4.7 months for patients with low cytosolic concentrations, p=0.024, log-rank). Thus, high levels of survivin are mainly related with a poor response to endocrine therapy, but a good response to chemotherapy. This phenomenon might be related to the different functions of survivin. |
| | |
Authors:
|
Paul N Span; Vivianne C G Tjan-Heijnen; Peggy Manders; Doorlene van Tienoven; Jeffrey Lehr; Fred C G J Sweep |
Related Documents
:
|
15905797 - Association between alopecia and response to chemotherapy in patients with hodgkin lymp... 19748847 - Glutathione s-transferase polymorphisms and survival in african-american and white colo... 1383537 - The beneficial effect of dextran on anastomotic patency and flap survival in a strongly... 17071487 - Primary non-hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 11... 14631087 - Serum neuron-specific enolase and s-100b protein in cardiac arrest patients treated wit... 17161557 - Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy technique... |
Publication Detail:
|
Type: Journal Article Date: 2006-03-16 |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: 98 ISSN: 0167-6806 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 2006 Jul |
Date Detail:
|
Created Date: 2006-07-12 Completed Date: 2006-10-26 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 223-30 Citation Subset: IM |
Affiliation:
|
Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. p.span@ace.umcn.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Aromatase Inhibitors / therapeutic use Breast Neoplasms / chemistry, drug therapy*, mortality Enzyme-Linked Immunosorbent Assay Female Humans Medroxyprogesterone Acetate / therapeutic use Microtubule-Associated Proteins / analysis* Middle Aged Neoplasm Proteins / analysis* Tamoxifen / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Aromatase Inhibitors; 0/BIRC5 protein, human; 0/Microtubule-Associated Proteins; 0/Neoplasm Proteins; 10540-29-1/Tamoxifen; 71-58-9/Medroxyprogesterone Acetate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells.
Next Document: Polymer nano-engineering for biomedical applications.